MLH1 and urinary bladder carcinoma: Wu's study found that patients with bladder cancer in the high‐risk group of the irlncRNA signature had high expression of MSH6 (MutS homolog 6) and MHL1 (MutL homolog 1), a low TMB, and low expression of programmed cell death 1 (PD‐1) and programmed cell death 1 ligand 1 (PD‐L1).27